Lv6
1650 积分 2024-04-14 加入
Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer
7小时前
待确认
NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer
1个月前
已完结
Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
1个月前
已完结
Feasibility of ctDNA-guided precision neoadjuvant therapy in locally advanced rectal cancer: Insights from the ongoing CINTS-R trial
3个月前
已完结
Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147)
3个月前
已关闭
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
6个月前
已完结
Cluster of differentiation 147 (CD147) as potential membrane protein biomarker for bladder cancer cells
8个月前
已完结
皖公网安备34019202002308
